COMMUNIQUÉS West-GlobeNewswire

Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026
07/05/2026
TOS-358 is a covalent, pan-mutant, a -selective PI3K inhibitor designed to address key limitations of existing PI3K a therapies which include limited mutation coverage and poor tolerability First presentation of [...]
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
07/05/2026
Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer REDWOOD CITY, Calif., May 06, 2026 (GLOBE [...]
Memora Claims Evaluated: New Memory Health Report Examines Advanced Brain Health Supplement for Preventing Cognitive Decline
07/05/2026
How Bacopa Monnieri, Lion's Mane, Ginkgo Biloba, Rhodiola Rosea, and Panax Ginseng Support Memory Function and Cognitive Wellness in 2026 Tallmadge, OH, May 06, 2026 (GLOBE NEWSWIRE) -- These statements have not been [...]
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss First Quarter 2026 Financial Results on May 8, 2026
07/05/2026
FREDERICK, Md., May 06, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report [...]
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
06/05/2026
1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year 1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income ( 1) of $40.7 Million, 22% Year-Over-Year Growth [...]
iMDx to Release First Quarter 2026 Results on May 13, 2026
06/05/2026
NASHVILLE, Tenn., May 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report first quarter 2026 financial results after the market closes on [...]
Pennant Reports First Quarter 2026 Results
06/05/2026
Conference Call and Webcast scheduled for tomorrow, May 7, 2026 at 10:00 am MT EAGLE, Idaho, May 06, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated [...]
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
06/05/2026
One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026 New Data from Both Cohorts of the MyPEAK™-1 Phase 1b/2 Trial of TN-201 for [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
06/05/2026
PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission [...]
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
06/05/2026
Generated first quarter XDEMVY ® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales and peak sales [...]
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
06/05/2026
– NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Mineralys [...]
InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference
06/05/2026
MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced plans to present [...]
Zevra Reports First Quarter 2026 Financial Results and Corporate Update
06/05/2026
Q1 2026 net revenue of $36.2 million , a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 million Company to [...]
electroCore Announces First Quarter 2026 Financial Results
06/05/2026
First quarter 2026 net sales of $9.6 million, an increase of 43% over $6.7 million in the first quarter 2025 Net loss of $5.3 million with Adjusted EBITDA net loss improving 24% from prior-year period to $2.3 million [...]
OraSure Announces First Quarter 2026 Financial Results
06/05/2026
BETHLEHEM, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for [...]
BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance
06/05/2026
MENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, [...]
Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance
06/05/2026
MENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, [...]
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
06/05/2026
Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of people suffering [...]
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
06/05/2026
Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentation [...]

Pages